Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002100 · ClinicalTrials.gov registry record · Phase 1

Phase I/II Study of Curdlan Sulfate

A Phase 1 study of HIV Infections, sponsored by AJI Pharma U.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00002100: Completed Phase 1 study of HIV Infections, sponsored by AJI Pharma U.

NCT00002100 is a Phase 1 study of HIV Infections that has completed, run by AJI Pharma U. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002100, a Phase 1 study of HIV Infections, has completed, sponsored by AJI Pharma U.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

Conditions Studied

HIV Infections

Interventions

  • DRUG Curdlan sulfate

Study Locations (1)

California

  • ViRx Inc - San Francisco

Trial Details

FieldValue
Phase Phase 1
AJI Pharma U

2 total trials

What the finished NCT00002100 record still lists

NCT00002100 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Curdlan sulfate is the first listed.

NCT00002100 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002100 about?

NCT00002100 is a clinical study titled "Phase I/II Study of Curdlan Sulfate". To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

What is the current status of trial NCT00002100?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00002100 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002100?

The interventions under investigation include: Curdlan sulfate (DRUG).

Who is sponsoring clinical trial NCT00002100?

This trial is sponsored by AJI Pharma U, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002100 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002100, the US trial registry maintained by the National Library of Medicine. NCT00002100 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.